Treatment of Glucagonoma That Is Unresectable or Has Locoregionally Advanced Disease and/or Distant Metastases

When glucagonoma cannot be surgically removed or has spread to regional structures or distant sites, a structured approach addresses both tumor control and the systemic hormonal effects of the disease.

Clinical Scenario

This protocol applies to glucagonoma that is unresectable, has locoregional advanced disease, and/or has distant metastases — settings where curative resection is not achievable upfront or where disease has extended beyond the primary site.

Treatment Goals

Control of blood glucose levels
Resolution of flushing, diarrhea, and dermatitis
Stable disease on imaging

Approach Overview

Management centres on hormonal agents to control glucagonoma-related symptoms and tumor activity, together with metabolic management and consideration of surgical intervention when feasible. The complete regimen — agent selection, sequencing, and full clinical criteria — is available in the structured protocol.

Instant Access to Structured Evidence-Based Regimens

References

Octreotide LAR or lanreotide (if not already receiving) (NE-H 3 of 12)

For symptom and/or tumor control, octreotide LAR 20–30 mg IM or lanreotide 120 mg SC every 4 weeks. Higher doses have been shown to be safe. For breakthrough symptoms, octreotide 100–250 mcg SC TID can be considered.

Resect metastases and primary if possible and clinically indicated (NE-F)

For patients with glucagonoma, treatment of hyperglycemia and diabetes is necessary, especially to control blood sugar level prior to surgery.

Flushing, diarrhea, hyperglycemia, dermatitis, hypercoagulable state

View source ↗